Progress in oncolytic viruses modified with nanomaterials for intravenous application

In oncolytic virus (OV) therapy, a critical component of tumor immunotherapy, viruses selectively infect, replicate within, and eventually destroy tumor cells. Simultaneously, this therapy activates immune responses and mobilizes immune cells, thereby eliminating residual or distant cancer cells. However, because of OVs' high immunogenicity and immune clearance during circulation, their clinical applications are currently limited to intratumoral injections, and their use is severely restricted. In recent years, numerous studies have used nanomaterials to modify OVs to decrease virulence and increase safety for intravenous injection. The most commonly used nanomaterials for modifying OVs are liposomes, polymers, and albumin, because of their biosafety, practicability, and effectiveness. The aim of this review is to summarize progress in the use of these nanomaterials in preclinical experiments to modify OVs and to discuss the challenges encountered from basic research to clinical application. Oncolytic virus; nanomaterials; drug delivery; tumor treatment; intravenous application

Automated summary

Oncolytic virus (OV) therapy is a critical component of tumor immunotherapy. By modifying OVs with nanomaterials, their toxicity can be reduced and safety can be increased, expanding their clinical applications.